Targeted therapy and hematological malignancy
نویسندگان
چکیده
منابع مشابه
Multidrug resistance in hematological malignancy.
The recent treatment of hematological malignancies appears to be unsatisfactory in child and adult patients with acute myeloid leukemia and adult patients with acute lymphocytic leukemia. A major problem in the treatment of leukemia is caused by the development of drug resistance to chemotherapeutic agents, which is already present at diagnosis or after chemotherapy as a minimal residual diseas...
متن کاملThe role of BCL11B in hematological malignancy
The B-cell leukemia/lymphoma 11B (BCL11B) gene is a member of the BCL family which plays a crucial role in the development, proliferation, differentiation and subsequent survival of T cells. BCL11B gene alterations are related to malignant T cell transformation that occurs in hematological malignancies. Remarkably, the BCL11B gene is responsible for the regulation of the apoptotic process and c...
متن کاملCoagulase-negative Staphylococci in Hematological Malignancy
Erik Ahlstrand (2013): Coagulase-negative Staphylococci in Hematological Malignancy. Örebro Studies in Medicine 95. Bacterial infections are common in hematological malignancy. Coagulasenegative staphylococci (CoNS) are among the most prevalent causes of bacteremia in patients with hematological malignancies. In this thesis, different aspects of CoNS in hematological malignancy have been studie...
متن کاملAngiotropic lymphoma: a rare hematological malignancy.
Correspondence: Ass. Professor Paraskevi Roussou, 3rd University Department of Medicine, “Sotiria” Hospital, 152 Mesogion Avenue, Athens GR-11527, Greece. Fax: international +301-7719981. A56-year-old woman was referred to us complaining of painful subcutaneous nodules in the lower extremities during the last three months. The nodules appeared a year ago. The physical examination disclosed palp...
متن کاملChallenges in the Role of Gammaglobulin Replacement Therapy and Vaccination Strategies for Hematological Malignancy
Patients with chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) are prone to present with antibody production deficits associated with recurrent or severe bacterial infections that might benefit from human immunoglobulin (Ig) (IVIg/SCIg) replacement therapy. However, the original IVIg trial data were done before modern therapies were available, and the current indications do not take...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Targeted Oncology
سال: 2009
ISSN: 1776-2596,1776-260X
DOI: 10.1007/s11523-008-0098-1